Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of the humanized monoclonal antibody against the interleukin-2 receptor alpha subunit (IL-2R-Alpha; Zenapax [daclizumab]) on inflammatory activity in the CNS [central nervous system] in MS [multiple sclerosis] in a baseline-to-treatment, cross-over, MRI [magnetic resonance imaging]-controlled single center phase I/II trial.

Next Previous
X
Search
Trial Profile

Effect of the humanized monoclonal antibody against the interleukin-2 receptor alpha subunit (IL-2R-Alpha; Zenapax [daclizumab]) on inflammatory activity in the CNS [central nervous system] in MS [multiple sclerosis] in a baseline-to-treatment, cross-over, MRI [magnetic resonance imaging]-controlled single center phase I/II trial.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daclizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use

    • Most Recent Events

    • 16 Dec 2008 Actual start date changed from 3 Sep 1999 to 1 Sep 1999 as reported by ClinicalTrials.gov.
    • 21 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Oct 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top